Cover Image

Evaluation of psoriasis area and severity index as a proxy for bio­markers of systemic disease under treatment with tumour necrosis factor-alpha and interleukin 12/23 antagonists in patients with psoriasis: a retrospective cohort study of 186 treatment cycles

The efficacy of psoriasis treatments is usually evaluated using the Psoriasis Area and Severity Index (PASI). However, there is a lack of systematic statistical assessments of PASI as a proxy for systemic disease in individual patients. Therefore, a retrospective study of 186 treat­ments with adalim...

Full description

Saved in:
Bibliographic Details
Main Authors: Hoffmann, Jochen (Author) , Knoop, Christian (Author) , Schäkel, Knut (Author) , Enk, Alexander (Author) , Hadaschik, Eva (Author)
Format: Article (Journal)
Language:English
Published: Apr 27, 2021
In: Acta dermato-venereologica
Year: 2021, Volume: 101, Pages: 1-7
ISSN:1651-2057
DOI:10.2340/00015555-3814
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.2340/00015555-3814
Verlag, lizenzpflichtig, Volltext: http://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-3814
Get full text
Author Notes:Jochen H.O. Hoffmann, Chriatian Knoop, Knut Schäkel, Alexander H. Enk and Eva N. Hadaschik
Description
Summary:The efficacy of psoriasis treatments is usually evaluated using the Psoriasis Area and Severity Index (PASI). However, there is a lack of systematic statistical assessments of PASI as a proxy for systemic disease in individual patients. Therefore, a retrospective study of 186 treat­ments with adalimumab, etanercept, and ustekinumab for psoriasis (341 patient-years) was performed.
Item Description:Gesehen am 25.02.2022
Physical Description:Online Resource
ISSN:1651-2057
DOI:10.2340/00015555-3814

Similar Items